Vasant (Vas) Narasimhan, M.D., currently holds the position as Novartis' Global Head of Drug Development and Chief Medical Officer.
(Source: Novartis)
Basel/Switzerland — Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position. The Board of Directors has appointed Vasant (Vas) Narasimhan, M.D., Global Head of Drug Development and Chief Medical Officer, as CEO of Novartis, effective February 1, 2018. Dr. Narasimhan is a member of the Executive Committee and joined Novartis in 2005.
Mr. Jimenez, who has been CEO since 2010, joined the company in 2007. He first led the Consumer Health Division, and then held the position of Division Head, Novartis Pharmaceuticals. Mr. Jimenez will step down as CEO, effective January 31, 2018, and will be available for advice and support at the request of the Chairman of the Board of Directors or the CEO until he retires from Novartis on August 31, 2018.
The designated CEO has held numerous leadership positions across Novartis in commercial, drug development and strategy roles. Prior to his current role he served as Head of Development for Novartis Pharmaceuticals. Before joining Novartis in 2005, he worked at McKinsey & Company. He received his medical degree from Harvard Medical School in the US and obtained a master's degree in public policy from Harvard's John F. Kennedy School of Government.
In addition, he holds a bachelor's degree in biological sciences from the University of Chicago, also in the US. During and after his medical studies, he worked extensively on a range of health issues in developing countries. Dr. Narasimhan is an elected member of the US National Academy of Medicine. He is a US citizen born in 1976, married with 2 children, and lives in Basel, Switzerland.
Unfold for details of your consent
Stand vom 23.03.2021
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.
:quality(80)/p7i.vogel.de/wcms/39/b1/39b157a0602e7b8753999978d543d12e/0105429509.jpeg "0105429509")
:quality(80)/p7i.vogel.de/wcms/87/78/8778c95da1a93c577b8ee63b89a9ea92/0105379690.jpeg "0105379690")
:quality(80)/p7i.vogel.de/wcms/ec/71/ec71bc17999b7c321892010fe023712b/0105339441.jpeg "0105339441")
:quality(80)/p7i.vogel.de/wcms/44/d7/44d72fef6e90321f370e563387cd427d/0105332698.jpeg "0105332698")
:quality(80)/p7i.vogel.de/wcms/b1/53/b153013223a2288a96d789b1a70735c9/0105419200.jpeg "0105419200")
:quality(80)/p7i.vogel.de/wcms/4e/2a/4e2a144319130f1f0c04813c371f0939/0105291950.jpeg "0105291950")
:quality(80)/p7i.vogel.de/wcms/6a/65/6a6510b5ec7cb55ae4d825798f9d7f21/0105162306.jpeg "0105162306")
:quality(80)/p7i.vogel.de/wcms/b4/b6/b4b6d220aabd3340cd195449d6e6086e/0105234071.jpeg "0105234071")
:quality(80)/p7i.vogel.de/wcms/09/44/0944a2cfbe9b84e0ebd699e0770817df/0105068313.jpeg "0105068313")
:quality(80)/p7i.vogel.de/wcms/25/e0/25e03fe398377396b773b00f17b4b81e/0105058832.jpeg "0105058832")
:quality(80)/p7i.vogel.de/wcms/5f/cb/5fcb52d64a4963e20764893ee85b2ebb/0105025395.jpeg "0105025395")
:quality(80)/p7i.vogel.de/wcms/4d/b2/4db210ba4bc55954c41c2154d375d909/0105010131.jpeg "0105010131")
:quality(80)/p7i.vogel.de/wcms/0d/3b/0d3b418adb4c7af71022c52878dd8fdf/0104800005.jpeg "0104800005")
:quality(80)/images.vogel.de/vogelonline/bdb/1963700/1963732/original.jpg)
:quality(80)/images.vogel.de/vogelonline/bdb/1963500/1963506/original.jpg "Healthy adults eating a diverse diet with at least eight to ten grams of soluble fiber a day have fewer antibiotic-resistant microbes in their guts. Soluble fiber is found in foods such as grains, beans, lentils, nuts, and some fruits and vegetables.")
:quality(80)/images.vogel.de/vogelonline/bdb/1963400/1963459/original.jpg "Thermo Scientific Dionex Ionpac CS21-Fast-4m ion exchange column.")
:quality(80)/p7i.vogel.de/wcms/37/41/3741dd1b4190cb8974b4139fe072da8a/0105429534.jpeg "0105429534")
:quality(80)/p7i.vogel.de/wcms/c2/8d/c28d67c9b76f30205e80e2826942060a/0105389353.jpeg "0105389353")
:quality(80)/p7i.vogel.de/wcms/c0/5d/c05d1614f8d9f488c68a6a681e16d0d9/0105371581.jpeg "0105371581")
:quality(80)/p7i.vogel.de/wcms/94/c8/94c8112fdd1958527b65b3300c61f0c0/0105334243.jpeg "0105334243")
:quality(80)/images.vogel.de/vogelonline/bdb/1710600/1710675/original.jpg "Discover how to set yourself up for success when performing balance-based density determination of solids such as jewelry and precious metals.")
:quality(80)/images.vogel.de/vogelonline/bdb/1682500/1682579/original.jpg "The new XPR Analytical balance redesigned to meet the needs of laboratory technicians of working fast and lean.")
:quality(80)/images.vogel.de/vogelonline/bdb/1677000/1677080/original.jpg "Enhance your weighing accuracy, comfort and productivity with the redesigned XPR Analytical balance.")
:quality(80)/images.vogel.de/vogelonline/bdb/1961400/1961452/original.jpg "Joachim Holm is the new managing director of the Shimadzu office in Denmark.")
:quality(80)/images.vogel.de/vogelonline/bdb/1945200/1945250/original.jpg "Dr. Philip Ma is Chief Executive Officer, President, and Founder of Prognomiq.")